Since early 1974 a comparitive study of penicillamine and gold in the management of severe seronegative juvenile chronic polyarthritis has been in progress at this Unit (Ansell & Hall 1977) . Assessments, including height, were made one month before commencing therapy, and subsequently at 0, 1, 3, 9, 12 and 24 months after therapy began. Penicillamine was introduced at 50 mg daily or 50 mg b.d. according to whether or not the child was below 20 kg in weight, and gradually increased to 450 mg in those under 20 kg and 600 mg in those 20 kg and over. Every effort was made to maintain this dosage for the full period unless the child went into remission, when the dose was reduced to a maintenance level, but never less than 250 mg daily. The effect of therapy on growth over a one and two year period is reviewed. It should be appreciated that, when severe, the disease can cause a general retardation of growth (Ansell & Bywaters 1956) and that this is further ,b /,. / aggravated by the administration ofcorticosteroid 54 10; SW ,,/ on a daily divided-dose regime (Ansell 1968 ). It was therefore necessary to divide our patients into /, , ' those who had or had not been given corticosteroids, and also those who were getting them at the time of starting penicillamine. Nine girls and 3 boys had not received corticosteroids at any time, but in 2 cases severe contractures of the hips and knees made accurate measurement impossible. icillaimne mg.
In 6 of the 10 available for assessment there was excellent control of the disease process at the end of one year, and these patients were all growing satisfactorily (Figs 1 and 2). When the disease activity increased despite therapy with penicillamine the tendency to fall-off in growth corresponded with the number ofjoints involved and height of the ESR (Fig 3) . Eight girls and 3 boys were receiving various regimens of corticosteroids at the commencement of their therapy but in one case severe contractures of hips and knees made adequate height assessment impossible. The one who was withdrawn from steroids as a result of her disease 8 I l O becoming less active showed the expected growth 7 8 9 10 spurt after withdrawal. Six result of crush fracture vertebre while on daily corticosteroid; he was transferred to alternate day prednisone together with penicillamine; this has allowed gradual resumption of growth and reformation of vertebra is just commencing (Fig 5) . The remaining 2 were already into their puberty growth spurt on alternate day prednisone (1) and ACTH (1), and this continued.
Summary
When the disease state improves during penicillamine therapy, resumption of growth occurs; if activity persists despite therapy, the expected falloff in growth due to active Still's disease continues. Penicillamine does not interfere with the growth spurt after withdrawal of corticosteroid therapy or with the maintained slow growth during alternate-day steroid therapy.
DISCUSSION

Dr R Grahame (London): What about the growth of patients on gold therapy?
Dr Ansell: It is much the same; if the disease can be controlled, growth in height is resumed, but if the disease is not controlled, the growth rate slowly decreasesit does not drop suddenly, as it does with corticosteroids. I have nol yet analysed all the patients on gold in this series. This work is still very much in progress, but the patients behaved no differently from those reported originally on gold therapy in the early to mid-1960s.
Dr D Sumner (Leeds): What happens to growth hormone in these children? Dr Ansell: If they take very high, daily divided doses of corticosteroids, continued over a prolonged periodby which I mean above 20 mg/ dayresting growth hormone is low and they do not have a normal hypoglycamic response. Most of the children with whom I am dealing are on about 10 mg on alternate days, and these have normal resting growth hormone and normal hypoglycwmic response. It is in our lupus juveniles who need enormous doses of prednisone that there is failure of growth hormone compared with other children. It is not known why corticosteroids interfere with growth. It is obviously related to intactness ofthe hypothalamic pituitary adrenal axis because, as soon as this can be demonstrated to be fully intact again, this is the time at which the children start growing again. Dr R N Maini (London): Some of the audience will have seen a letter we wrote to the Lancet from Charing Cross Hospital about a patient with rheumatoid arthritis who developed aplastic anemia while on penicillamine therapy for rheumatoid arthritis (Bourke, Maini, Griffiths & Scott (1976) Lancet ii, 515). The details of this patient appear in the Lancet. Briefly, she commenced treatment with D-penicillamine in September 1974, with gradual increase in dose to 750 mg daily. After six months the drug was withdrawn for three weeks because of a pruritic rash, and reintroduced at a daily dose of 150 mg daily (April 1975) . On this dose she kept well until she had a transient rash in February 1976 which cleared up spontaneously. In March 1976 her arthritis flared up again and the dose was increased to 250 mg a day and apparently controlled her disease. Table 1 shows, however, that she It is important to stress that the patient was only receiving penicillamine and aspirin (the latter for over 15 years), and no other drugs could be incriminated in her terminal illness, unlike some of the other reported patients who have developed aplasia possibly related to penicillamine therapy. She was, as you see, on a small dose of penicillamine and was under proper surveillance.
Dr I A Jaffe (New York): The aplastic aneemia patient should be treated in hospital with reverse isolation, meticulous nursing, blood and platelet transfusions, if required, broad spectrum antibiotic coverage and prayer. There is absolutely no evidence that corticosteroids are of any benefit, but there is every evidence that large doses of corticosteroids will further depress the one thing that these patients neednamely their resistance to microbial infection.
Dr Maini: The point is well taken. This patient was treated as above and did not receive corticosteroids until about 48 hours before her death. In the end we felt that we had to try steroids because thrombocytopenia and bleeding had become one of the major problems in her management.
Dr Lyle: We do not have time to discuss this subject further, but I wanted Dr Maini to draw attention to it to remind everyone that this is a really dangerous side-effect of penicillamine and one to which rheumatoid patients seem to be the most susceptible.
